Evotec International GmbH has reported new prodrugs of NLRP3 inflammasome inhibitors potentially useful for the treatment of inflammation, asthma, hypertension, myocardial infarction, neurological disorders, silicosis, graft-vs.-host and metabolic diseases.

Asahi Kasei Therapeutics Corp. has identified new tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists potentially useful for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, hidradenitis suppurativa, ulcerative colitis and Crohn's disease.

Tennor Therapeutics Ltd. has patented new compounds potentially useful for the treatment of bacterial infections.

Brightgene Bio-Medical Technology Co. Ltd. has divulged new gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of neurodegeneration, bone, metabolic and cardiovascular disorders.

Zhejiang Jingke Pharmaceuticals Co. Ltd. has disclosed new deuterated isoindoline compounds acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands. They are described as potentially useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, dry macular degeneration, rheumatoid arthritis, asthma, Alzheimer's and Parkinson's disease.

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis and gastroenteritis.

Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors (TRK) and/or proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or hepatocyte growth factor receptor (HGFR; MET) and/or macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) and/or ALK tyrosine kinase receptor inhibitors found to be potentially useful for the treatment of cancer and pain.

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as AP2-associated protein kinase 1 (AAK1) inhibitors that are potentially useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, diabetic peripheral neuropathy, postherpetic neuralgia (PHN) and schizophrenia.

Hangzhou Innogate Pharma Co. Ltd. has patented inhibitors of histone acetyltransferase KAT5 (Tip60) and/or KAT6A (MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) and/or KAT7 (HBO-1; MYST-2) and/or KAT8 (hMOF; MYST-1) reported to be useful for the treatment of cancer.